To investigate retinal vessels functionality in patients with acute central serous chorioretinopathy (CSC) undergoing oral eplerenone or photodynamic therapy (PDT) using Retinal Vessel Analyzer (RVA) and Dynamic Vessel Analyzer (DVA), respectively.
Methods
Treatment naïve acute CSC patients presenting between May 2017 and June 2017 were recruited. A complete ophthalmological examination was performed in all participants before and after oral eplerenone (eplerenone group) or half-dose PDT (PDT group).
Results
Eighteen eyes of 18 patients affected by acute CSC underwent either oral eplerenone (10 eyes of 10 patients, 47.6 ± 8.9 years old) or half-dose PDT (8 eyes of 8 patients, 57.4 ± 6.2 years old), respectively. After 2 months of treatment, non-significant variations of static retinal vessels analysis, dynamic arterial and venous dilatation were reported in eplerenone group. Similarly, in PDT group non-significant variations of static retinal vessels analysis, dynamic arterial and venous dilatation were found after 2 months of treatment.
Conclusions
Static and dynamic retinal functionalities in acute CSC may not be significantly improved by oral eplerenone and half-dose PDT. Although their choroidal effects, these treatments could not exert a significant effect on retinal vessels motility. Thus, both local and systemic therapies might not help avoiding the onset of vascular and other retinal known alterations of CSC.
KitzmannASPulidoJSDiehlNN,et al.The incidence of central serous chorioretinopathy in olmsted county, minnesota, 1980–2002. Ophthalmology2008; 115: 169–173. DOI:10.1016/j.ophtha.2007.02.032.
2.
NicholsonBNobleJForooghianF,et al.Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol2013; 58: 103–126. DOI:10.1016/j.survophthal.2012.07.004.
3.
DadaTSpaideRF. Systemic findings associated with central serous chorioretinopathy [1] (multiple letters). Am J Ophthalmol2000; 130: 379. DOI:10.1016/S0002-9394(00)00423-2.
4.
MindelJBouzasEAKaradimasP,et al.THERAPEUTIC REVIEWS Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol2002; 47(5): 431–448.
5.
TewariHKGadiaRKumarD,et al.Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Investig Ophthalmol Vis Sci2006; 47: 3474–3478. DOI:10.1167/iovs.05-1246.
6.
KurodaSIkunoYYasunoY, et al.Choroidal thickness in central serous chorioretinopathy. Retina2013; 33: 302–308. DOI:10.1097/IAE.0b013e318263d11f.
7.
GuyerDRYannuzziLSlakter JS,et al.Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol1994; 112(8). DOI:10.1001/archopht.1994.01090200063023.
8.
PrunteCFlammerJ. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol1996; 121(1): 26–34. DOI:10.1016/S0002-9394(14)70531-8.
9.
ScheiderANasemannJELundOE. Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. Am J Ophthalmol1993; 115: 50–56. DOI:10.1016/S0002-9394(14)73524-X.
10.
SpaideRFHallLHaasA, et al.ICG Videoangiography of older patients with CSCR. Retina1996; 16: 201–213. DOI:10.1097/00006982-199616030-00004.
11.
YangLJonasJBWeiW. Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol2013; 91: 358–362. DOI:10.1111/aos.12059.
12.
PintoCSousaKOliveiraE, et al.Foveal and extrafoveal effects of half-dose photodynamic therapy in chronic central serous chorioretinopathy: a cohort study. Semin Ophthalmol2022; 37: 153–157. DOI:10.1080/08820538.2021.1931357.
13.
IaconoPDa PozzoSVaranoM,et al.Photodynamic therapy with verteporfin for chronic central serous chorioretinopathy: a review of data and efficacy. Pharmaceuticals2020; 13: 1–18. DOI:10.3390/ph13110349.
14.
ShinJYWooSJYuHG,et al.Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina2011; 31: 119–126. DOI:10.1097/IAE.0b013e3181e378f2.
15.
SacconiRTomassoLCorbelliE, et al.Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: a OCT-angiography study. Eye2019; 33: 1809–1817. DOI:10.1038/s41433-019-0511-2.
16.
Carvalho-RecchiaCAYannuzziLANegrãoS, et al.Corticosteroids and central serous chorioretinopathy. Ophthalmology2002; 109: 1834–1837. DOI:10.1016/S0161-6420(02)01117-X
17.
BousquetEBeydounTZhaoM,et al.Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina2013; 33: 2096–2102. DOI:10.1097/IAE.0b013e318297a07a.
18.
ZucchiattiISacconiRParravanoMC, et al.Eplerenone versus observation in the treatment of acute central serous chorioretinopathy: a retrospective controlled study. Ophthalmol Ther2018; 7: 109–118. DOI:10.1007/s40123-018-0121-2.
19.
SacconiRBaldinGCarnevaliA, et al.Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Eye2018; 32: 734–742. DOI:10.1038/eye.2017.295.
20.
BorrelliEZuccaroBZucchiattiI, et al.Optical coherence tomography parameters as predictors of treatment response to eplerenone in central serous chorioretinopathy. J Clin Med2019; 8: 1271.
21.
YannuzziLAShakinJLFisherYL,et al.Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology1984; 91: 1554–1572. DOI:10.1016/S0161-6420(84)34117-3.
22.
BattistaMBorrelliEParravanoM, et al.OCTA Characterisation of microvascular retinal alterations in patients with central serous chorioretinopathy. Br J Ophthalmol2020; 104: 1453–1457. DOI:10.1136/bjophthalmol-2019-315482.
23.
AltunelOArifogluHB. Evaluation of retinal vessel diameters in eyes with active central serous chorioretinopathy. Retina2021; 41: 861–866. DOI:10.1097/IAE.0000000000002932.
24.
SacconiRCasaluciMBorrelliE, et al.Multimodal imaging assessment of vascular and neurodegenerative retinal alterations in type 1 diabetic patients without fundoscopic signs of diabetic retinopathy. J Clin Med2019; 8: 1409. DOI:10.3390/jcm8091409.
25.
QuerquesGBorrelliESacconiR, et al.Functional and morphological changes of the retinal vessels in Alzheimer’ s disease and mild cognitive impairment. Sci Rep2019; 9: 63. DOI:10.1038/s41598-018-37271-6
26.
GarhoferGBekTBoehmAG, et al.Use of the retinal vessel analyzer in ocular blood flow research. Acta Ophthalmol2010; 88: 717–722. DOI:10.1111/j.1755-3768.2009.01587.x.
27.
TomassoLBenattiLRabioloA, et al.Retinal vessels functionality in eyes with central serous chorioretinopathy. Br J Ophthalmol2018; 102: 210–214. DOI:10.1136/bjophthalmol-2017-310398.
28.
AbeSTamaiMKaritaK,et al.Increased and decreased choroidal blood flow elicited by cervical sympathetic nerve stimulation in the cat. Jpn J Physiol1995; 45: 347–353. DOI:10.2170/jjphysiol.45.347.
29.
RoybalCNSledzEElshatoryY, et al.Dysfunctional autonomic regulation of the choroid in central serous chorioretinopathy. Retina2018; 38: 1205–1210. DOI:10.1097/IAE.0000000000001677
30.
SpaideRF. Choroidal blood flow: review and potential explanation for the choroidal venous anatomy including the vortex vein system. Retina2020; 40: 1851–1864. DOI:10.1097/IAE.0000000000002931.
31.
YeXLatiesAMStoneRA. Peptidergic innervation of the retinal vasculature and optic nerve head. Investig Ophthalmol Vis Sci1990; 31: 1731–1737.
32.
BrinksJvan DijkEHCMeijerOC,et al.Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmol2022: 1–14. DOI:10.1111/aos.15112.
33.
ChanW-MLamDSCLaiTYY,et al.Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol2003; 87(12): 1453–1458.
34.
RazaviSSouiedEHCavalleroE,et al.Assessment of choroidal topographic changes by swept source optical coherence tomography after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol2014; 157: 852–860. DOI:10.1016/j.ajo.2013.12.029.
35.
ZhaoMCélérierIBousquetE, et al.Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest2012; 122: 1–8. DOI:10.1172/JCI61427DS1.
36.
BousquetEZhaoMDaruichA,et al.Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: review of the pre-clinical and clinical evidence. Exp Eye Res2019; 187: 107754. DOI:10.1016/j.exer.2019.107754.
